MAST is Less Effective in Children Under 6 Years for Diagnosing Allergic Sensitization
The Multiple Allergen Simultaneous Test (MAST) shows reduced sensitivity in younger children compared to older children, making it a suboptimal screening tool for children under 6 years, particularly those under 5 years with atopic dermatitis who require more targeted diagnostic approaches.
Age-Related Diagnostic Considerations
Children Under 5 Years with Atopic Dermatitis
For children under 5 years with moderate-to-severe atopic dermatitis, targeted testing for specific food allergens (milk, egg, peanut, wheat, and soy) is recommended over broad screening panels like MAST 1. This recommendation applies when:
- Persistent atopic dermatitis despite optimized topical therapy
- Reliable history of immediate reaction after specific food ingestion
The guideline explicitly advises against widespread screening tests in young children due to poor predictive value, which would lead to clinically irrelevant results and unnecessary dietary restrictions 1.
Performance Data in Pediatric Populations
The available evidence on MAST performance shows important age-related limitations:
In children aged 4-19 years, MAST demonstrated a sensitivity of only 59% compared to skin testing, with specificity of 97% 2. This sensitivity is notably lower than RAST (67% sensitivity) in the same age group, and both methods are less sensitive than skin prick tests for detecting allergen-specific IgE.
In children up to 2 years old with atopic dermatitis, MAST showed almost perfect agreement with ImmunoCAP for certain food allergens (egg white, hazelnuts, potato, cow's milk proteins, wheat flour, and soybean) 3. However, this study specifically evaluated children already diagnosed with atopic dermatitis, not general screening effectiveness.
Critical Limitations in Young Children
Physiological Considerations
Younger children (particularly those under 5-6 years) have developing immune systems that may produce lower levels of specific IgE antibodies, potentially falling below MAST detection thresholds. The correlation studies showing good agreement between MAST and reference methods were conducted primarily in older children (mean age 31.1 years in one study) or mixed populations 4, 5, 6.
Diagnostic Accuracy Issues
MAST cannot detect certain clinically important allergen components that are crucial for accurate diagnosis in pediatric populations. Recent evidence demonstrates that MAST fails to screen for wheat-dependent exercise-induced anaphylaxis (detecting only 33.3% of cases) and completely misses α-gal syndrome (0% detection) 7. This highlights fundamental limitations in the allergen panel composition.
Recommended Diagnostic Approach by Age
For Children Under 5 Years:
- Start with clinical history: Focus on timing of reactions (immediate vs. delayed), specific foods implicated, and severity of atopic dermatitis
- Use targeted testing: ImmunoCAP or equivalent for specific allergens based on clinical suspicion (milk, egg, peanut, wheat, soy)
- Avoid broad screening panels: MAST and similar multiplex tests have poor predictive value in this age group 1
- Consider oral food challenges: These remain the gold standard when testing results are equivocal or to confirm tolerance 8
For Children 6 Years and Older:
- MAST may be considered for initial screening when multiple allergen sensitization is suspected
- Confirm positive MAST results with component-resolved diagnostics or skin prick testing
- Recognize sensitivity limitations: MAST still shows only 59% sensitivity even in older children 2
Common Pitfalls to Avoid
- Over-reliance on screening panels in young children: This leads to false-positive results and unnecessary dietary restrictions that can harm nutritional status 1
- Assuming negative MAST excludes allergy: The low sensitivity means clinically significant allergies may be missed, particularly in children under 6 years
- Testing without clinical indication: General population screening is not recommended regardless of age 1
- Ignoring component-specific allergens: MAST cannot detect omega-5 gliadin, α-gal, and other important molecular components 7
Evidence Quality Assessment
The guideline evidence 1 provides the strongest framework, explicitly recommending against broad screening in children under 5 years. The research evidence on MAST performance 3, 2, 4 consistently shows reduced sensitivity compared to reference methods, with the most concerning data showing complete failure to detect certain allergen types 7. The convergence of guideline recommendations and performance data strongly supports using targeted, component-specific testing rather than MAST in children under 6 years.